Abstract
Deep learning is a promising tool that uses nonlinear transformations to extract features from high-dimensional data. Although deep learning has been used in several genetic studies, it is challenging in genome–wide association studies (GWAS) with high-dimensional genomic data. Here we propose a novel three-step approach for identification of genetic variants using deep learning to identify phenotype-related single nucleotide polymorphisms (SNPs) and develop accurate classification models. In the first step, we divided the whole genome into non-overlapping fragments of an optimal size and then ran Convolutional Neural Network (CNN) on each fragment to select phenotype-associated fragments. In the second step, using an overlapping window approach, we ran CNN on the selected fragments to calculate phenotype influence scores (PIS) and identify phenotype-associated SNPs based on PIS. In the third step, we ran CNN on all identified SNPs to develop a classification model. We tested our approach using genome-wide genotyping data for Alzheimer’s disease (AD) (N=981; cognitively normal older adults (CN) =650 and AD=331). Our approach identified the well-known APOE region as the most significant genetic locus for AD. Our classification model achieved an area under the curve (AUC) of 0.82, which outperformed traditional machine learning approaches, Random Forest and XGBoost. By using a novel deep learning-based GWAS approach, we were able to identify AD-associated SNPs and develop a better classification model for AD.
Author summary Although deep learning has been successfully applied to many scientific fields, deep learning has not been used in genome–wide association studies (GWAS) in practice due to the high dimensionality of genomic data. To overcome this challenge, we propose a novel three-step approach for identification of genetic variants using deep learning to identify disease-associated single nucleotide polymorphisms (SNPs) and develop accurate classification models. To accomplish this, we divided the whole genome into non-overlapping fragments of an optimal size and ran a deep learning algorithm on each fragment to select disease-associated fragments. We calculated phenotype influence scores (PIS) of each SNP within selected fragments to identify disease-associated significant SNPs and developed a disease classification model by using overlapping window and deep learning algorithms. In the application of our method to Alzheimer’s disease (AD), we identified well-known significant genetic loci for AD and achieved higher classification accuracies than traditional machine learning methods. This study is the first study to our knowledge to develop a deep learning-based identification of genetic variants using fragmentation and window approaches as well as deep learning algorithms to identify disease-related SNPs and develop accurate classification models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). In addition, this work was supported, in part, by grants from the National Institutes of Health (NIH) and includes the following sources: P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057, R01 LM012535 and R03 AG063250. The funders played no role in the design of the study, analysis, and interpretation of the data or in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ADNI study was approved by the IRBs of all of the participating institutions, and all participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¥ Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Email addresses: Taeho Jo: tjo{at}iu.edu
Kwangsik Nho: knho{at}iupui.edu
Paula Bice: pbice{at}indiana.edu
Andrew J Saykin: asaykin{at}iupui.edu
Data Availability
Data from the ADNI are available from the ADNI website (adni.loni.usc.edu).
